The following is information for clinicians wishing to prescribe cabotegravir as PrEP, and relates to the submission of cabotegravir PrEP prior approval (Blueteq) forms.
The current prior approval (Blueteq) form for cabotegravir as PrEP is in the Innovative Medicines Fund (IMF) format, in which prescribers must select their name from a drop-down list. There is no facility in this form to enter names in a free-text box.
The IMF Blueteq form will be in place for 90 days as per the NICE TA1106 implementation period until the routine commissioning of cabotegravir as PrEP on 3rd February 2026. After this period, the Blueteq form will be updated into the standard high cost drug CHCD) routine commissioning format and will allow prescribers to enter their details in a free-text box. Submission of Blueteq forms does not need to be repeated after 3rd February.
Prescribers are advised to contact cdf@blueteq.co.uk to request that their name to be added to the dropdown list.